Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience

• Published in: BMC infectious diseases 2022-02, Vol.22 (1), p.113-113, Article 113
• Main Authors: Quirino, Angela, Scaglione, Vincenzo, Marascio, Nadia, Mazzitelli, Maria, Garofalo, Eugenio, Divenuto, Francesca, Serapide, Francesca, Bruni, Andrea, Lionello, Rosaria, Pavia, Grazia, Costa, Chiara, Giancotti, Aida, Peronace, Cinzia, Longhini, Federico, Russo, Alessandro, Liberto, Maria Carla, Matera, Giovanni, Torti, Carlo, Trecarichi, Enrico Maria
• Format: Article
• Language: English
• Subjects: Anti-infective agents; Antiinfectives and antibacterials; Antimicrobial agents; Antimicrobial therapy; Assaying; Automation; Biological Assay; Biological systems; Blood culture; Blood stream infections; Care and treatment; Comparators; Diagnosis; Dosage and administration; Empirical analysis; ESKAPE; Humans; Infections; Infectious diseases; Innovations; Magnetic resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mortality; Patients; Retrospective Studies; Risk factors; Sepsis; Sepsis - diagnosis; Sepsis - drug therapy; T2Dx; Therapy; United States
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-022-07096-w

T2Dx was approved by the US Food and Drug Administration for the rapid detection of a modified panel of ESKAPE bacterial species or Candida spp. causing bloodstream infection (BSI). We performed a retrospective, observational study from January 1, 2018 to December 31, 2019 of all hospitalised patients with suspected BSI who underwent assessment using T2Dx in addition to standard blood culture (BC). T2-positive patients (cases) were compared to a matched group of patients with BSI documented only by BC (1:2 ratio) to investigate the possible impact of T2Dx on the appropriateness of empirical antimicrobial therapy and 21-day mortality. In total, 78 T2Dx-analysed samples (49 patients) were analysed. The T2Dx assay result was positive for18 patients and negative for 31 patients. The concordance rates of the T2Bacteria Panel and T2Candida Panel results with those of standard BC were 74.4% and 91.4%, respectively. In the matched analysis, inappropriate empiric antimicrobial therapy administration was significantly less frequent in cases than in comparators (5.5% vs. 38.8%). The 21-day mortality rate was twofold lower in cases than in comparators (22.2% vs. 44.4%), although the difference was not significant. No other analysed variables were significantly different between the two groups. This study illustrated that T2Dx might be associated with an increase in the appropriateness of empiric antimicrobial therapy in patients with BSI. Further studies are needed to evaluate whether the T2Dx assay can improve patient outcomes.